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Abstract The pediatric bone sarcomas osteosarcoma and
Ewing sarcoma represent a tremendous challenge for the
clinician. Though less common than acute lymphoblastic
leukemia or brain tumors, these aggressive cancers account
for a disproportionate amount of the cancer morbidity and
mortality in children, and have seen few advances in sur-
vival in the past decade, despite many large, complicated,
and expensive trials of various chemotherapy combina-
tions. To improve the outcomes of children with bone
sarcomas, a better understanding of the biology of these
cancers is needed, together with informed use of targeted
therapies that exploit the unique biology of each disease.
Here we summarize the current state of knowledge re-
garding the contribution of receptor tyrosine kinases, in-
tracellular signaling pathways, bone biology and
physiology, the immune system, and the tumor microen-
vironment in promoting and maintaining the malignant
phenotype. These observations are coupled with a review
of the therapies that target each of these mechanisms, fo-
cusing on recent or ongoing clinical trials if such infor-
mation is available. It is our hope that, by better
understanding the biology of osteosarcoma and Ewing
sarcoma, rational combination therapies can be designed
and systematically tested, leading to improved outcomes
for a group of children who desperately need them.
Key Points
Many of the therapeutic targets important in
common adult cancers are also important for
osteosarcoma and Ewing sarcoma.
Preclinical and early clinical trial data are available
to support the use of many of these agents in
children.
Combination therapy has generally been safe in
children and should be evaluated further with more
agents.
1 Introduction
Osteosarcoma (OS) is the most common type of primary
bone cancer [1], occurring primarily in adolescents and
young adults, with a peak incidence in the second decade
of life. Standard therapy consists of surgical removal of any
resectable primary tumor and metastases, combined with
6–9 months of neoadjuvant and adjuvant chemotherapy
[2]. Current chemotherapy regimens include four agents:
doxorubicin (adriamycin), cisplatin, and high-dose
methotrexate with leukovorin rescue [3–5]. Some clin-
icians have used ifosfamide for patients with high-risk or
metastatic disease [6], though the recently completed
EURAMOS (European and American Osteosarcoma
Study) showed definitively that the addition of ifosfamide
to adjuvant MAP (methotrexate, doxorubicin [adriamycin],
and cisplatin) chemotherapy for OS patients with poor
necrosis increased toxicity without improving survival
(results presented at the annual meeting of the Connective
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many, 2014). Although modern multimodal therapy yields
70 % survival for patients without overt metastasis at di-
agnosis, outcome for metastatic OS remains poor: fewer
than 30 % of patients presenting with metastases survive
5 years after diagnosis [7].
Ewing sarcoma (ES) is the second most common bone
malignancy. It is characterized typically by a translocation
between chromosomes 22 and 11, generating a fusion be-
tween the EWS and FLI1 genes [8]. ES occurs through a
broad age range, from infants to older adults, with a peak
incidence in the second decade of life and a slightly higher
incidence rate in males [9, 10]. ES arises most frequently in
bones, but occasionally develops in soft tissues [11]. In-
tensive multimodal treatment with combination che-
motherapy, surgery, and radiation has increased the overall
survival rate from less than 10 % to around 50 % [12–15].
The current standard of care for newly diagnosed ES
consists of chemotherapy with five drugs: vincristine/dox-
orubicin/cyclophosphamide alternating with ifosfamide
and etoposide [16, 17]. Standard therapy should include 17
cycles of chemotherapy, though ‘good-risk’ patients with
localized disease in an extremity may be safely reduced to
14 cycles. Chemotherapy cycles should be compressed to
every 2 weeks rather than every 3 in those patients who can
tolerate it—typically younger patients—as compressed
timing has a proven survival advantage [18].
While intensive multi-agent chemotherapy has improved
survival compared with the pre-chemotherapy era, there
have been few recent improvements in outcome for either
non-metastatic patients or those who present with metastatic
disease, and it has been difficult even for therapies that prove
beneficial, such as mifamurtide [19], to obtain regulatory
approval. However, in recent years, great advances have
been made in understanding the molecular basis of patho-
genesis and progression of pediatric bone sarcomas. This
new understanding has been achieved in parallel with an
explosion of novel therapies developed specifically to in-
hibit cancer-associated genes and pathways. Identification
of key regulatory pathways and molecular biomarkers
yielded dramatic changes in outcome for several adult
cancers, but childhood cancer, and bone sarcomas in par-
ticular, have largely been sidelined in this revolution.
To help make these important discoveries relevant for
childhood bone sarcomas, it is important to have an under-
standing of the role of each signaling pathway in the biology
of the disease, as well as the available agents that target these
processes. Priority was given to those pathways for which
there is good information about the relevance to OS or ES,
and those agents for which data are available. Where pos-
sible, we describe the reported results of clinical trials
completed with novel therapies, especially highlighting
those that involve children or are specific for bone sarcoma.
We highlight the studies that we have been able to identify
that use targeted therapy for bone sarcoma, whether for
children or adults, since some treating physicians may
choose to apply knowledge gained from these adult studies
to their care of children with similar conditions. We have
also included the results of some novel therapies that have
been proven ineffective in clinical trials. To provide coher-
ence to this broad topic, we have organized this review into
sections highlighting processes at the plasma membrane,
intracellular signaling pathways, bone metabolism, and the
environmental and immune interactions of bone sarcoma.
2 Surface Markers for Osteosarcoma (OS):
Receptor Tyrosine Kinases
Receptor tyrosine kinases (RTKs) are cell-surface proteins
that act as receptors for various extracellular ligands, in-
cluding growth factors, hormones, and cytokines. In addi-
tion to regulating normal cellular processes, RTKs and the
intracellular signaling pathways they activate are critical to
oncogenesis for many types of cancer [20]. Deregulation of
a variety of RTKs, including insulin-like growth factor
receptor type I (IGF-1R), vascular endothelial growth
factor receptor (VEGFR), human epidermal growth factor
receptor 2 (HER2, also called ERBB2), and platelet-
derived growth factor receptor (PDGFR), have been im-
plicated in pediatric bone sarcomas [21, 22]. Note that,
because of the biology of the process affected, VEGFR
inhibition is discussed in the environmental interactions
section, rather than with RTKs, since the target tissue af-
fected by these agents is the tumor vasculature rather than
the tumor cells themselves. Since RTKs were the first
molecular targets attacked in the current wave of small
molecule therapeutics, with the greatest range of drugs
approved or in development, each of the RTK pathways
relevant to OS and ES biology is considered below.
2.1 Insulin-Like Growth Factor Receptor Type I
(IGF-1R)
IGF-1R mediates cell differentiation, proliferation, and
apoptosis in human cancer by activating two major onco-
genic signaling cascades: the phosphoinositide 3-kinase
(PI3K) pathway and the mitogen-activated protein kinase
(MAPK) pathway [23, 24]. Elevated expression of IGF-1R
has been observed in most OS and ES cell lines and tumor
samples [25–27]. Overexpression of IGF-1R and its ligand
IGF-1 in pediatric bone sarcomas is correlated with a
poorer prognosis, and IGF pathway inhibition impeded
tumor growth and metastasis in preclinical models [28, 29].
Current therapeutic approaches directed against the IGF-
1R pathway can be grouped into three categories:
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monoclonal antibodies targeting IGF-1R, IGF ligand-neu-
tralizing antibodies, and small-molecule tyrosine kinase
inhibitors. At present, eight different anti-IGF-1R
monoclonal antibodies (mAbs) have been or are currently
being evaluated in phase I/II clinical trials, and one of
which is being evaluated in pediatric patients (Table 1).
Although their safety has been proven in pediatric patients,
these IGF-1R antagonists displayed limited or no clinical
benefit as monotherapy for patients with advanced bone
sarcomas [30–37]. Investigations using IGF-1R-targeted
agents in combination are ongoing, though it is not clear
what benefit these studies will show. Further, since these
agents showed no benefit in common adult malignancies,
their development has been abandoned by the pharma-
ceutical industry, suggesting that they are unlikely to be
available for future bone sarcoma patients.
An alternative approach to inhibit IGF signaling is to
neutralize the bioactivity of IGF ligands IGF-I and -II with
mAbs. In preclinical studies, these agents achieved more
effective inhibition of IGF signaling than IGF-1R mAbs by
blocking binding of IGF-I and -II ligands to IGF-1R and
insulin receptor (IR)-A [38, 39]. Two neutralizing anti-
bodies against IGF-I/II are available: MEDI-573 and
BI836845. A phase I clinical trial for MEDI-573 in adult
patients with advanced solid tumors demonstrated stable
disease in 13 of 39 patients [40]. Currently, five phase I
clinical trials of BI836845 are ongoing in adult patients
with various solid tumors, but there have been no specific
studies in OS or ES patients. Since IGF-II and IGF-2R can
also be overexpressed in OS and ES, these patients might
benefit from therapies that target both IGF ligands [27, 41].
In addition to mAbs, small-molecule inhibitors of IGF-
1R are also being developed. Some of these agents also
inhibit IR-A-dependent tumor growth [42]. Novel IGF-1R
tyrosine kinase inhibitors include linsitinib, XL-228,
INSM-18, GSK1904529A, GSK1838705A, and BMS-
554417, all of which have shown promising results in pe-
diatric sarcoma models during preclinical studies [22]. As
yet, no pediatric clinical trial data have been reported for
these agents.
2.2 Human Epidermal Growth Factor Receptor
2 (HER2) and the ERBB Family
HER2 is one of the four RTKs in the epidermal growth
factor receptor (HER/EGFR/ERBB) family and has an
essential role in tumor growth. In recent years, targeted
therapies against HER2 have achieved significant
therapeutic benefits in the treatment of several solid tu-
mors. However, data have been conflicting regarding ex-
pression of HER2 in OS and ES and its association with
clinical outcome. While some reports demonstrated mini-
mal expression of HER2 in tumor samples of pediatric
bone sarcomas or lack of correlation between HER2 ex-
pression level and patient outcome [43–48], other studies
have suggested that HER2 is highly expressed in up to
40 % of OS cases and 20 % of ES cases and its overex-
pression is correlated with metastases and poor prognosis
[46, 49–55]. One possible reason for these disparate results
may be purely technical: the Her-2 antigen is susceptible to
oxidative degradation, such that it is essentially unde-
tectable 6 months after slides are cut [56, 57]. The safety of
the HER2 mAb trastuzumab in combination with standard
chemotherapy has been shown in a phase II clinical trial for
OS, but no benefit was seen [58]. There is no clear evi-
dence of therapeutic benefit for this agent in bone sarcoma,
and no basis for treating bone sarcoma patients with it
except in the context of a clinical trial. In addition to the
antibody approach, small-molecule tyrosine kinase in-
hibitors of the ERBB family such as erlotinib, lapatinib,
afatinib, neratinib and dacomitinib are currently in clinical
development [59]. Since HER4, another member of the
HER family, has emerged in recent years as an essential
regulator in OS, ES, and other pediatric solid tumors [60–
62], the pan-Her small-molecule inhibitors (afatinib, da-
comitinib, and neratinib) may represent a more effective
approach in treating pediatric bone sarcomas than EGFR-
specific small-molecule inhibitors such as erlotinib [63,
64].
2.3 Platelet-Derived Growth Factor Receptor
(PDGFR)
The PDGF family of signaling molecules consists of five
ligands (PDGF-AA, -BB, -AB, -CC, -DD), and two RTKs
(PDGFR-a and -b) [65]. In OS and ES, PDGF/PDGFR
signaling has a central role in tumor growth and metastasis,
and overexpression of PDGFR-a and -b is often correlated
with poor prognosis [66–69]. Imatinib, a potent inhibitor of
c-Kit and PDGFR, has been evaluated in phase II clinical
trials for treating bone sarcomas. However, this compound
failed to demonstrate significant antitumor activity as a
single agent in children with recurrent OS and ES [70, 71].
Since blocking PDGF/PDGFR signaling is not sufficient to
inhibit tumor progression in patients, other multi-targeted
RTK inhibitors such as dasatinib are currently being
studied in phase I/II studies for patients with advanced
sarcomas (Table 1).
3 Intracellular Signaling Pathways
Cellular signaling is a complex process by which extra-
cellular events alter intracellular physiology and gene ex-
pression. While there is a great diversity of transmembrane
receptors and other agents that can initiate signaling,
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Table 1 Active clinical trials in osteosarcoma and Ewing sarcoma [180–183]
Target Class Drug Clinical trial Age (y)
IGF-1R Anti-IGF-1R antibodies Cixutumumab with temsirolimus Phase II: Recurrent or refractory solid tumors in
pediatric patients (NCT01614795)
[1 to 30
VEGF/VEGFR Anti-VEGF antibodies Bevacizumab with chemotherapy Phase II: OS (NCT00667342) [180] Up to 30
Bevacizumab with chemotherapy Phase II: ES family of tumor and desmoplastic
small round cell tumors (NCT01610570)
[1
VEGF inhibitors Endostar (recombinant human
endostatin) with chemotherapy
Phase II: OS (NCT01002092) 12–60
Small-molecule TKIs Pazopanib Phase II: OS metastatic to the lung
(NCT01759303)
[60
Pazopanib Phase II: Refractory solid tumors in children,
adolescents, and young adults (NCT01956669)
[1 to 18
Regorafenib Phase II: Refractory liposarcoma, OS, and ES
(NCT02048371)
[18
Sorafenib with irinotecan Phase I: Relapsed or refractory solid tumors in
pediatric patients (NCT01518413)
2–22
Sorafenib with everolimus Phase II: Relapsed and non-resectable high-grade
OS (NCT01804374) [181]
[18
PDGFR Small-molecule TKIs Imatinib mesylate Phase II: Refractory or relapsed solid tumors in
children (NCT00030667)
Up to 30
Dasatinib Phase II: Advanced sarcomas including ES
(NCT00464620)
[13








Phase Ib/II: Advanced sarcoma [18
Vorinostat and etoposide Phase I/II: Relapsed/refractory sarcomas \4 to 21
Valproic acid and bevacizumab
with gemcitabine and docetaxel
Phase I/II: Locally advanced, unresectable or
metastatic sarcoma (NCT01106872) Note: this
is a combination of HDACi with VEGF
inhibition
[18
Bone metabolism Bisphosphonates Zoledronic acid/zoledronic acid
with ‘standard chemotherapy’
Phase II/III: High-grade OS (NCT00691236) 18–65
Zoledronic acid with
chemotherapy
Phase III: High-grade OS (NCT00470223) 5–50







Phase II: High-risk OS (NCT01886105) 13–65
Radium-223 dichloride Phase I/II: High-risk OS (NCT01833520) [15
mTOR Small-molecule
inhibitors
Everolimus Phase II: Refractory or relapsed OS
(NCT01216826)
Up to 21










RO4929097 with vismodegib Phase I/II: Advanced or metastatic sarcoma




Vismodegib with RO4929097 See above [18
Src Small-molecule
inhibitors
Saracatinib Phase II: Recurrent OS localized to the lung
(NCT00752206)
15–74
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common pathways often are used by diverse receptors, and
therapeutic approaches have been developed to attack the
most vital pathways in cancer. In recent years, there have
been many advances in our understanding of how these
pathways function in OS and ES, and which are essential
for the cancer cell. The intracellular signaling pathways
important for OS and ES are discussed here.
3.1 Ezrin
As a member of the ezrin/radixin/moesin (ERM) family,
ezrin links the actin cytoskeleton to the plasma membrane.
Gene microarray studies demonstrated increased Ezrin
expression in metastatic OS lesions [72]. Further, high
ezrin expression in OS patients, both human and canine,
was correlated with poor overall survival [72, 73]. Khanna
and colleagues [73, 74] demonstrated that early steps in OS
pulmonary metastases are dependent on ezrin-mediated
protein kinase B (AKT) and MAPK signaling, and reduc-
tion of ezrin expression by a short hairpin RNA (shRNA)
decreased the survival of metastatic cells in the lung. The
relevance of ezrin in metastatic disease has been validated
for other sarcomas, including ES, although in this model
ezrin mediates metastasis by signaling through the
AKT/mammalian target of rapamycin (mTOR) pathway
[75]. Two small-molecule ezrin inhibitors have been suc-
cessfully studied in vitro and in vivo using OS models, but
these agents still await testing in clinical trials [76].
3.2 Mammalian Target of Rapamycin (mTOR)
The mTOR is a serine/threonine kinase and integral ef-
fector of the PI3K–AKT signaling pathway. It regulates
cell cycle progression and protein synthesis among other
steps during carcinogenesis [77]. Rapamycin (sirolimus)
and its derivatives have been effective at reducing tumor
growth in OS and ES murine models and in clinical trials
[78–82] and has been used as a radiosensitizer for OS [83].
A recent phase III clinical trial tested ridaforolimus in adult
sarcoma patients who had achieved objective responses
with prior chemotherapy [84]. For the 702 patients treated
on that study (only 10 % had bone sarcoma), ridaforolimus
increased progression-free survival by 28 % (p\ 0.001),
but greatly increased grade 3 or higher toxicities, especially
stomatitis, cytopenias, and infection. The report does not
provide a subset analysis for the bone sarcoma patients.
Several clinical trials using mTOR inhibitors in combina-
tion therapies are in progress (Table 1).
3.3 Steroid Receptor Co-Activator (Src)
The steroid receptor co-activator (Src) family of kinases is
expressed at high levels and is constitutively active in
many cancers, including OS and ES. Pharmacologic inhi-
bition of Src in vitro led to apoptosis and decreased inva-
sion, migration, and adhesion of OS and ES cells; however,
these results were not reproducible using OS in vivo
Table 1 continued
Target Class Drug Clinical trial Age (y)
PARP PARP inhibitors/
alkylating agents
Olaparib with temozolomide Phase I: Recurrent or metastatic ES following
failure of prior chemotherapy (NCT01858168)
[18
Olaparib Phase II: Recurrent of metastatic ES following
failure of prior chemotherapy (NCT01583543)
[182]
[18
Niraparib with temozolomide Phase I: Previously treated, incurable ES
(NCT02044120)
[13
BMN-673 with temozolomide Phase I/II: Refractory or recurrent malignancies
including ES in younger patients
(NCT02116777)
13–30
Immunotherapy Interferons Low-dose IFNa-2b with
thalidomide
Phase II: Soft tissue sarcoma or bone sarcoma
(NCT00026416)
[18
Immunostimulants Aerosol IL-2 Phase I/II: Pulmonary metastases of solid tumors
including OS and ES (NCT01590069)
12–50
GD2-based therapies Activated T cells armed with
GD2-bispecific antibody





Phase I: OS and ES in children and adolescents
(NCT00743496) [183]
Up to 21
T cells expressing an anti-GD2
chimeric antigen receptor
Phase I: GD2? solid tumors in children and young
adults (NCT02107963)
1–35
ES Ewing sarcoma, HDACi histone deacetylase inhibitor, IFN interferon, IGF-1R insulin-like growth factor receptor type 1, IL interleukin,
mTOR mammalian target of rapamycin, OS osteosarcoma, PARP poly ADP ribose polymerase, PDGFR platelet-derived growth factor receptor,
Src steroid receptor co-activator, TKIs tyrosine kinase inhibitors, VEGF vascular endothelial growth factor, VEGFR VEGF receptor, y years
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models, pointing at possible redundancy in activation of
downstream effectors like focal adhesion kinase (FAK)
[85–88]. A dual inhibitor of BCR-Abl and Src, dasatinib
has been used in one clinical trial where the maximum
tolerated dose was determined but no objective responses
were observed [89]. Clinical trials are in progress with
either dasatinib alone or in combination therapy or with
saracatinib, an Src-specific inhibitor.
3.4 Notch
Signaling via the Notch pathway is essential for the devel-
opment of most organ systems, including for both neuroge-
nesis [90] and osteoblast maturation [91]. Activation of the
Notch pathway is required for vasculogenesis during tumor
progression in ES [92]. Notch has been linked to increased
invasion and metastasis in OS, in part through promoting a
tumor-initiating cell phenotype [93–95]. Membrane-bound
Notch activation upon ligand binding occurs through a two-
step proteolytic process carried by ADAMs family proteases
followed by gamma-secretase cleavage, releasing a soluble
intracellular Notch that can regulate transcription [96]. A
phase I clinical trial in advanced solid malignancies using a
gamma-secretase inhibitor (GSI) showed anti-tumor activity
and a low toxicity profile [97]. A phase I/II clinical trial using
a GSI in combination with an inhibitor of the hedgehog
pathway for the treatment of metastatic sarcomas is currently
recruiting patients. In considering the effects of GSI, one
should recall that GSIs inhibit the processing of several re-
ceptors that effect metastasis, including Her-4, CD44,
E-cadherin, and N-cadherin [98].
3.5 Hedgehog
The hedgehog pathway is important for embryonic devel-
opment and is dysregulated in various cancers. High ex-
pression of the hedgehog ligands and targets are observed in
both OS and ES models, where this pathway is activated in
both a ligand-dependent and a ligand-independent manner
[99–101]. Interestingly, EWS-FLI1 signaling is mediated
through GLI, an effector and transcription regulator in the
hedgehog pathway [102]. Inhibition of the hedgehog path-
way in vitro and in ES and OS xenografts has been suc-
cessful and warrants further research [100, 103]. In a recent
clinical trial in adult patients with advanced solid tumors, an
oral inhibitor of the hedgehog pathway was fairly well
tolerated [104]. While the skeletal abnormalities seen in
young mice briefly treated with hedgehog pathway in-
hibitors might raise concerns about pediatric applications
for these agents [105], most OS and ES patients are close to
their expected adult size at diagnosis, suggesting that these
concerns should not preclude study.
3.6 Histone Deacetylase Inhibitors
Histone deacetylase inhibitors (HDACi) have been studied
in cancer due to their effects in promoting transcription of
tumor suppressor genes silenced during malignant trans-
formation. Phase I clinical trials in pediatric patients with
relapsed or refractory solid tumors using pracinostat or
vorinostat monotherapy showed no tumor responses [106,
107]. Patient trials are underway using combination ther-
apy with HDACi and adjuvant chemotherapies and may
have greater promise (Table 1). Additionally, treatment
with HDACi in preclinical models caused upregulation of
natural killer (NK) cell recognition markers and of the
apoptosis-promoting Fas receptor, resulting in increased
sensitivity to NK-mediated killing [108, 109]. These results
warrant further investigation in clinical trials of HDACi
plus NK cells.
3.7 Ras
Ras proteins are small GTPases that regulate cell prolif-
eration, apoptosis, and survival by activating multiple
downstream signaling pathways, including MAPK. Though
constitutively active, Ras mutations are uncommon in pe-
diatric sarcomas; targeting Ras reduced tumor growth,
possibly due to the many pathways requiring Ras relay
signals [110–113]. Reolysin is an oncolytic virus that se-
lectively targets Ras transformed cells, and xenografts
showed tumor growth inhibition by reolysin used alone or
with chemotherapy agents [114]. A phase II study in sar-
coma patients has been completed. While partial results
were presented at the American Society of Clinical On-
cology (ASCO) annual meeting in 2009 [115], there have
been no peer-reviewed publications for sarcoma since that
abstract was presented.
3.8 MDM2
MDM2 is a ubiquitin ligase that regulates p53 activity by
targeting this tumor suppressor for proteasomal degrada-
tion. Nutlins are small molecules that inhibit MDM2 and
p53 binding, leading to increased availability of p53.
Treatment using nutlins have been effective in OS and ES
models, inducing apoptosis and cell cycle arrest [116–118].
RG7112, a nutlin family member, induced tumor regres-
sion in ES models, but no objective response was observed
with OS models [119]. Recently, a phase I clinical trial
using RG7112 in patients with relapsed or refractory tu-
mors was completed, though results have yet to be
reported.
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4 Targeting Bone Metabolism
Tumor growth and metastasis often require constant in-
teractions between tumor cells and their surrounding mi-
croenvironments [54, 120–123]. Therapeutic agents that
target the bone environment and modulate bone metabo-
lism have demonstrated some efficacy in pediatric bone
sarcomas.
4.1 Bisphosphonates
Bisphosphonates, which inhibit the mevalonate pathway at
high concentrations and impede osteoclast-mediated bone
resorption through induction of osteoclast apoptosis, have
been shown to suppress tumor growth and pulmonary
metastasis of ES in preclinical models [124–128]. To date,
several types of bisphosphonates, including zoledronate,
pamidronate, and alendronate, displayed significant anti-
tumor activity in vitro and in vivo [129–132]. A phase II
study evaluating the combination of chemotherapy and
pamidronate for patients with OS demonstrated little im-
pact on patient survival [133]. However, pamidronate has
been shown to improve the durability of limb reconstruc-
tion [133]. In a recently completed phase I study, the ad-
dition of zoledronate to conventional multi-agent
chemotherapy was safe but failed to demonstrate statisti-
cally significant differences in event-free or overall sur-
vival in patients with newly diagnosed metastatic OS [134].
However, our clinical team has treated many patients with
bone metastasis of OS with zoledronate, and we have found
that patients usually do not develop new bone metastases
after receiving four to six doses of monthly zoledronate.
We also have the impression that the need for opiates
during palliation is reduced after patients receive bis-
phosphonates, suggesting that the clinical trials performed
to date may not have looked at the correct endpoints.
Currently, three phase II/III trials that evaluate the efficacy
of zoledronate as a single agent or as an adjuvant to che-
motherapy in localized and metastatic OS and ES are on-
going (Table 1).
4.2 Conjugated Radioisotopes
Conjugated radioisotopes such as Samarium (153Sm) lex-
idronam (Samarium-153 EDTMP) and radium-223
dichloride (Xofigo) have high specificity for bone uptake,
which allows for the local delivery of high-dose radiation
in bone tumors [135, 136]. Standard dose of Samarium-153
EDTMP was originally approved by the US FDA for pain
management in patients with bone metastases, and radium-
223 was recently approved for the treatment of castration-
resistant prostate cancer patients with symptomatic bone
metastases. Although radiation therapy is not widely used
in treatment for OS, high-dose conjugated radioisotopes are
under clinical investigation for their anti-tumor activities
against OS. In a follow-up study of 14 patients with os-
teoblastic OS, Samarium-153 EDTMP in combination with
the radiosensitizer gemcitabine induced short-term anti-
tumor response in eight patients [137]. Thus far, conju-
gated radioisotopes have no clear role in Ewing sarcoma.
The ongoing clinical trials for this class of agents include a
phase I/II study for radium-223 dichloride and a phase II
study for Samarium-153 EDTMP in combination with
external radiotherapy in high-risk OS (Table 1).
4.3 Denosumab
Among the signaling molecules that have been associated
with worse outcome in OS is the receptor activator of
nuclear factor-kb (RANK), along with its ligand (RANKL)
and decoy osteoprotegerin (OPG), which normally are
essential for regulation of the homeostasis between bone
lysis and formation during bone remodeling [138, 139].
High expression of RANKL is associated with reduced
survival in OS [140], and some OS cell lines have func-
tional RANK expression [141], allowing for possible au-
tocrine stimulation of this pathway. Inhibition of RANK
with shRNA reduced motility and anoikis resistance in OS
cell lines, while overexpression of RANK using a retroviral
vector increased OS cell motility without affecting prolif-
eration [142].
Denosumab is an mAb specific for human RANKL and
was developed initially to treat osteoporosis [143] and was
later found effective in treating painful bone metastasis
[144–147]. It was subsequently found to be an effective
treatment for giant cell tumor of bone [148], a benign but
destructive neoplasm in which transformed mononuclear
cells secrete RANKL, causing osteoclast hyperactivity. We
have found that denosumab can be effective in treating
painful bone metastasis in OS, which is in line with the
FDA-approved indication for the drug. Whether it will
have any direct effect against OS in patients remains to be
seen.
5 Environmental and Immune Interactions
of Bone Sarcoma
While initial studies of cancer biology took a purely cell-
autonomous view of the cancer problem and sought to
understand and then target the specific biology of the ma-
lignant cell, it is now abundantly clear that all cancers,
including bone sarcomas, exist in a complex environment
of non-malignant supporting cells like fibroblasts and en-
dothelial cells, non-cellular stromal elements and matrix
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proteins, and cellular and protein components of the innate
and adaptive immune system [149]. While malignant cells
may become resistant to conventional chemotherapy, they
still must evade the immune system and continue to recruit
a blood supply and engage their environment for tumors to
grow and spread [150]. Recent developments seek to better
understand these interactions and exploit them for therapy.
5.1 Immunotherapy
5.1.1 Mifamurtide
Muramyl tripeptide phosphatidyl ethanolamine (L-MTP-
PE or mifamurtide) is a synthetic peptide derived from the
cell wall of the Bacille Calmette-Guerin mycobacterium
that has potent immunostimulatory properties [151]. Li-
posomal encapsulation of MTP-PE with phospholipids that
include phosphatidyl serine specifically triggers uptake into
macrophages and monocytes [152], which then become
activated, increasing phagocytosis and secreting interleukin
(IL)-6, tumor necrosis factor (TNF)-a and other cytokines
[19, 151, 153]. A phase III clinical trial concluded that
addition of mifamurtide to standard chemotherapy leads to
an increase in the 6-year overall survival in primary OS
patients from 70 to 78 % [19]. Mifamurtide has been ap-
proved as an adjuvant for the treatment of primary OS in
Europe, Israel, Japan, and Mexico, among other places, but
has not been approved by the US FDA [151, 153, 154].
5.1.2 Sargramostim
Sargramostim, the granulocyte macrophage colony-s-
timulating factor (GM-CSF) is an immune modulator that
promotes the activation and recruitment of neutrophils,
monocytes, and other immune cells [155]. Promising
in vitro and in vivo preclinical studies with sargramostim
prompted a phase I clinical trial of inhaled sargramostim,
which demonstrated low toxicity [156–158]. However, a
phase II clinical trial did not show any survival benefit
compared with standard treatment regimes in OS and ES
patients [159, 160].
5.1.3 Other Immunomodulators
Conflicting results have been observed using interferon
(IFN)-a for OS treatment. Despite some promising early
studies [161], the good responder arm of the EURAMOS 1
trial proved there is no benefit of adjuvant IFN in OS pa-
tients [162]. Systemic treatment use of IL-2 has limited
effects in survival due to life-threatening side effects [163].
Aerosol IL-2 has been demonstrated to target metastatic
lung disease by recruiting NK cells to the lungs [164, 165].
A clinical trial using aerosol IL-2 in metastatic lung lesions
is underway (Table 1).
5.1.4 Other Immunotherapies
Other immunotherapy approaches currently being investi-
gated in clinical trials include tumor vaccines using tumor
antigens or autologous antigen-presenting cells loaded with
tumor antigens, T-cell and NK-cell adoptive therapy, and
targeted therapy using antibodies for tumor antigens (GD2)
or to enhance T-cell activation (ipilimumab) (Table 1).
Immunotherapy approaches provide exciting new avenues
for pediatric sarcoma treatment.
5.2 Environmental Interactions:
Matrix and Vasculature
Part of the pathogenesis of bone sarcomas includes the
ability to invade through extracellular matrix tissues and to
recruit a new blood supply as tumors grow [166]. As a part
of hematogenous metastasis, tumor cells must also gain
access to the endovascular space [91]. These activities
typically proceed through hijacking normal biological
processes that are then exploited by tumor cells to facilitate
their growth and spread [167].
5.2.1 Matric Metalloproteases
Matrix metalloproteases (MMPs) are important mediators
of invasion and metastatic disease. Expression of MMPs
allows tumor cells to effectively degrade extracellular
matrix, which in turn allows tumor growth and supple-
ments cancer cells with growth factors [168]. Enhanced
expression of MMPs is found in tumors, including pediatric
sarcomas [169]. Inhibition of MMP2 and MMP9 affects OS
and ES tumor growth and metastasis formation [7, 111,
169, 170]. MMPs inhibition has also been observed in
animal models using bisphosphonates [128, 168].
5.2.2 Vascular Endothelial Growth Factor Receptor
VEGF ligands and receptors, as crucial regulators of tu-
mor-associated angiogenesis and vasculogenesis, have
been observed to be overexpressed in OS and ES [27, 171],
relative to corresponding normal tissues. High levels of
VEGF were predictive of pulmonary metastasis and poor
prognosis for both diseases in several studies [172–174].
Preclinical efficacy of VEGF-based therapeutics, including
anti-VEGF antibodies and small-molecule inhibitors
against VEGFR, has been confirmed in pediatric bone
sarcomas [27, 175]. The anti-VEGF mAb bevacizumab
demonstrated some clinical benefit as monotherapy or in
combination with doxorubicin in patients with recurrent ES
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[176, 177]. Three phase II trials of bevacizumab in com-
bination with chemotherapy for patients with OS and ES
are currently underway. Further, several multi-kinase in-
hibitors that target VEGFR, including sunitinib, sorafenib,
pazopanib, dasatinib, and cediranib, have demonstrated
growth inhibition in OS models in preclinical studies [21].
Clinical trials of several of these compounds in bone sar-
comas are in progress (Table 1).
6 Discussion
Treatment of pediatric bone sarcomas is complex, requiring
multimodal therapy and a comprehensive approach, best
delivered in a medical center experienced in caring for
children with OS and ES. The field has certainly advanced
since chemotherapy became widely accepted in the treat-
ment of these diseases in the 1970s and 1980s, but our
inability to improve outcomes in the past 20 or more years
underscores the importance of finding new approaches.
It is now clear that cancer therapy, rather than focusing
on delivering toxins at maximally tolerated doses, needs to
exploit the expanding understanding of tumor biology, both
for the signaling within the cells themselves and the in-
teractions between cancer cells and their environment. At
the same time, the enthusiasm for novel therapies needs to
be tempered by the reality of assessing primarily those
agents that are likely to be brought forward for regulatory
approval. In this way, as a field, we can avoid the kinds of
disappointment that arose from the IGF-1R antibody
therapies, which ‘died on the vine’ not because of a lack of
efficacy in bone sarcoma, but because these agents did not
have an identified utility for a common adult malignancy
and were, therefore, financially non-viable for further de-
velopment. Even more important, good clinical trial design
needs to be supported by excellent preclinical evidence
[178] so we can avoid rushing into large, expensive clinical
trials in children that result in no improvement in outcome
and expose children to unnecessary toxicity [58]. However,
what should not impede progress is a misguided effort to
‘protect children from the risk’ of testing targeted therapies
when there is sound basis for the evaluation. For the most
part, children tolerate all therapies better than do adults,
presumably because they have less ‘wear and tear’ and are
generally more resilient than adults. Even the known child-
specific concerns, such as the reduced growth that is known
to result from samarium therapy [179] or that may be a
concern for hedgehog inhibitors [105], needs to be bal-
anced against the potential benefit to a patient with a poor
prognosis. As one parent of a 10-year-old girl with ad-
vanced OS seen in our institution articulated, ‘‘I would
rather have her alive and short than not have her at all’’.
The investigations most urgently needed now are what
treatments to apply during a minimal disease state for pa-
tients at high risk of relapse before overt treatment-resistant
metastases are identified. An ideal therapy would be
relatively non-toxic, allowing its use for a prolonged period
after cytotoxic therapy is complete, and would specifically
attack the signaling pathways that allow for prolonged
survival of treatment-resistant dormant tumor cells. Large
genomic studies and personalized therapy may help us to
identify those patients at greatest risk of recurrence, but
these approaches may not give insight into the biology of
dormancy, nor of putative cancer stem cells. The focus of
the field now needs to turn to understanding how OS and
ES persist in these patients, and which approaches would
best eradicate the remaining tumor cells at that stage.
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